Pfizer’s Paxlovid not included in China’s national insurance


              In this photo released by Xinhua News Agency, a doctor prescribes small-molecule COVID-19 drugs for an elderly patient at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, Wang Liyun, right, head of medical department and a staff member from nursing facility checks on the distribution list for small-molecule COVID-19 drugs at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              Workers help travelers fill out an electronic declaration of their COVID-19 health status in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              Travelers wearing face masks wait for their luggage in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              Travelers wearing face masks wait for their luggage in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              FILE - Doses of the anti-viral drug Paxlovid are displayed in New York on Aug. 1, 2022. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (AP Photo/Stephanie Nano, File)
            
              In this photo released by Xinhua News Agency, a pharmacist checks on a prescription at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, a doctor prescribes small-molecule COVID-19 drugs for an elderly patient at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, Wang Liyun, right, head of medical department and a staff member from nursing facility checks on the distribution list for small-molecule COVID-19 drugs at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              Workers help travelers fill out an electronic declaration of their COVID-19 health status in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              Travelers wearing face masks wait for their luggage in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              Travelers wearing face masks wait for their luggage in the international arrivals area at Beijing Capital International Airport in Beijing, Monday, Jan. 9, 2023. The first international travelers are arriving in China without the mandatory quarantine that had been imposed at the start of the pandemic three years ago after restrictions were lifted beginning on Sunday. (AP Photo/Mark Schiefelbein)
            
              FILE - Doses of the anti-viral drug Paxlovid are displayed in New York on Aug. 1, 2022. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (AP Photo/Stephanie Nano, File)
            
              In this photo released by Xinhua News Agency, a pharmacist checks on a prescription at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, a doctor prescribes small-molecule COVID-19 drugs for an elderly patient at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, Wang Liyun, right, head of medical department and a staff member from nursing facility checks on the distribution list for small-molecule COVID-19 drugs at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              FILE - Doses of the anti-viral drug Paxlovid are displayed in New York on Aug. 1, 2022. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (AP Photo/Stephanie Nano, File)
            
              In this photo released by Xinhua News Agency, a pharmacist checks on a prescription at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, a doctor prescribes small-molecule COVID-19 drugs for an elderly patient at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, Wang Liyun, right, head of medical department and a staff member from nursing facility checks on the distribution list for small-molecule COVID-19 drugs at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              In this photo released by Xinhua News Agency, a pharmacist checks on a prescription at a community health service center in Shanghai, China, Sunday, Jan. 8, 2023. China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Wang Xiang/Xinhua via AP)
            
              A security guard wearing a face mask and using a bike-sharing service carries his belonging rides across a street in Beijing, Monday, Jan. 9, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would've allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (AP Photo/Andy Wong)
            
              A nurse holds a drug talks to an elderly patient as patients with COVID symptoms receive intravenous drips at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Chinatopix Via AP)
            
              Family members look after their elderly relatives with COVID symptoms at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Chinatopix Via AP)
            
              Elderly patients with COVID symptoms receive intravenous drips at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Chinatopix Via AP)
            
              A nurse shows the drugs to a family members as elderly patients with COVID symptoms receive intravenous drips while using a ventilators at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Chinatopix Via AP)
            
              A woman with COVID symptoms receives intravenous drip while using a ventilator at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. (Chinatopix Via AP)
Pfizer’s Paxlovid not included in China’s national insurance